Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at approximately $6,865,863. The trade was a 14.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Trading Up 6.0 %

Shares of ROIV stock traded up $0.71 during trading hours on Friday, hitting $12.53. 11,220,827 shares of the company were exchanged, compared to its average volume of 5,857,028. Roivant Sciences Ltd. has a 52-week low of $8.61 and a 52-week high of $13.06. The firm has a fifty day simple moving average of $11.68 and a 200 day simple moving average of $11.32. The stock has a market capitalization of $9.27 billion, a price-to-earnings ratio of 2.10 and a beta of 1.24.

Institutional Trading of Roivant Sciences

Several hedge funds have recently made changes to their positions in ROIV. American International Group Inc. lifted its stake in shares of Roivant Sciences by 7,589.5% during the 1st quarter. American International Group Inc. now owns 450,065 shares of the company’s stock valued at $4,744,000 after buying an additional 444,212 shares in the last quarter. Magnetar Financial LLC bought a new position in shares of Roivant Sciences in the first quarter worth $1,576,000. Clearbridge Investments LLC grew its position in shares of Roivant Sciences by 51.3% in the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock valued at $19,666,000 after purchasing an additional 630,712 shares in the last quarter. Cetera Advisors LLC bought a new stake in shares of Roivant Sciences during the 1st quarter valued at $758,000. Finally, Point72 Asset Management L.P. boosted its stake in Roivant Sciences by 40.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after purchasing an additional 185,226 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ROIV. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.